Recent Updates — SCNX

Nasdaq notified Scienture Holdings that its common stock closed at or above $1.00 per share for ten consecutive trading days between October 5 and October 16, 2026, confirming the company has regained compliance with the Minimum Bid Price Requirement. Consequently, Nasdaq determined the delisting matter is closed and securities will remain listed. Separately, the company announced preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, a 256% increase from the prior quarter's $344,000, driven by the commercial launch of REZENOPY and continued sales growth of Arbli. Scienture Holdings is a specialty pharmaceutical company focused on developing and commercializing novel products.

Scienture Holdings executed a one-for-twenty-five reverse stock split of its common shares, effective at 12:01 a.m. Eastern Time on October 5, 2026. The action was taken to restore compliance with Nasdaq’s minimum bid price requirement and to make additional shares available for future issuance. Following the split, the company expects approximately 1,642,565 shares outstanding from a pre-split base of roughly 41 million. Fractional share interests were cashed out rather than issued as partial ownership. Scienture Holdings operates in the pharmaceutical industry, focusing on the development and commercialization of novel specialty products.

Scienture Holdings reported Q2 2026 revenue of $343,639, a 510% sequential increase from Q1's $56,325. Gross margin reached approximately 97.7%, while operating expenses decreased 41% year-over-year to $3.0 million. The net loss narrowed 58% to $2.8 million ($0.07 per share). Cash and equivalents rose to $11.2 million from $6.7 million at year-end 2025. The company launched REZENOPY™ nasal spray for opioid overdose treatment, securing formulary coverage with a national health plan. Scienture is a specialty pharmaceutical holding company focused on the commercialization of novel products.